Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

Video content above is prompted by the following questions:

• Dr. Brixner: At what point(s) in the product lifecycle do clinicians want/need to receive education from PDT manufacturers to effectively learn about, prescribe, and manage these digital therapies?
  • Is there a preference for this education to occur pre-approval, post-approval but pre-launch, at commercial launch, or continuously throughout the product’s market availability?
• Peterson: How do payers track and monitor prescribing and utilization patterns for covered PDTs?
  • Have payers had to adjust policies after initial PDT adoption due to inappropriate prescribing or utilization issues?
• How do you see value-based or risk-based contracts evolving now that larger pharma manufacturers are developing and commercializing PDTs?
  • In your experiences, how do the metrics used to evaluate the real-world performance of PDTs, such as engagement metrics and discontinuation rates, differ from the traditional metrics employed for molecular drug therapies?